Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GTC Biotherapeutics has reported that LFB Biotechnologies has agreed to include the recombinant human coagulation factor IX program in the existing collaboration between GTC and LFB. Factor IX is used to treat Type B hemophilia.
Subscribe to our email newsletter
Under their collaboration, both the costs and profits of this program will be shared between GTC and LFB. LFB will fund the final $500,000 license fee payment due to ProGenetics in the second quarter of 2008. GTC retains exclusive marketing rights in North America for recombinant factor IX and LFB will receive exclusive marketing rights in Europe with co-exclusive marketing rights in Japan.
Geoffrey Cox, chairman and CEO of GTC, said: “Our collaboration with LFB is a significant enablement in this process, not only in the benefits of financial support, but very importantly in the experience and expertise with plasma fractionated products which LFB brings to our collaboration.”